Search

Your search keyword '"Toto, Robert D."' showing total 71 results

Search Constraints

Start Over You searched for: Author "Toto, Robert D." Remove constraint Author: "Toto, Robert D." Publisher elsevier bv Remove constraint Publisher: elsevier bv
71 results on '"Toto, Robert D."'

Search Results

1. WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

2. WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL

6. A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project

7. Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation

8. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions

9. The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

10. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

11. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

12. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

13. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

14. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

15. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis

17. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

18. Rationale and design of the Kidney Precision Medicine Project

19. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

20. Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)

21. Alport Syndrome Classification and Management

26. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

27. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

28. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

30. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference

31. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

32. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

33. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume

35. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

47. Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial

Catalog

Books, media, physical & digital resources